Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LPO | P22079 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950780 | 0.89 | FDPS (0.41) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL27698626 | 0.87 | FDPS (0.40) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL7166348 | 0.84 | FDPS (0.46) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL2398203 | 0.84 | FDPS (0.46) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL20747217 | 0.84 | FDPS (0.38) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL7152443 | 0.82 | FDPS (0.44) | FDPSKMT2AMEN1LPOFNTA | |
| Water SCHEMBL29120398 | 0.82 | FDPS (0.44) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL2399728 | 0.82 | FDPS (0.44) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL2393253 | 0.82 | FDPS (0.44) | FDPSKMT2AMEN1LPOFNTA | |
| SCHEMBL2395476 | 0.82 | FDPS (0.44) | FDPSKMT2AMEN1LPOFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031658-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS INC. | 2019-01-31 | — | — | US | disclosed |
| US-20110021483-A1 | Platinum (IV) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021483-A1 | Platinum (IV) Complexes | OTC, OAT, SLC25A11 | FDPS 2194/4885KMT2A 3593/4885MEN1 974/4885 |
| US-20190031658-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | NNT, NAMPT, NNMT | FDPS 950/4885KMT2A 275/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.